<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552929</url>
  </required_header>
  <id_info>
    <org_study_id>P05974</org_study_id>
    <secondary_id>19.4.209B</secondary_id>
    <nct_id>NCT00552929</nct_id>
  </id_info>
  <brief_title>A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(P05974)</brief_title>
  <official_title>A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial was to establish the dose-response relation of Org 25969 given as
      a reversal agent of rocuronium or vecuronium at 1-2 PTC during sevoflurane anesthesia for
      Caucasian subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2005</start_date>
  <completion_date type="Actual">September 15, 2006</completion_date>
  <primary_completion_date type="Actual">September 15, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start of administration of Org 25969 / placebo to recovery of the T4/T1 ratio to 0.9</measure>
    <time_frame>After surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of administration of Org 25969 / placebo to recovery of the T4/T1 ratio to 0.7 and 0.8</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 Doses of placebo Administered at 1-2 PTC After Rocuronium or Vecuronium</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of ASA class 1 - 3;

          -  Subjects at least 20 years but under 65 years of age;

          -  Caucasian subjects;

          -  Subjects scheduled for elective surgery requiring muscle relaxation in supine position
             and under sevoflurane anesthesia with an anticipated duration of about 1.5- 3 hours;

          -  Subjects who had given written informed consent.

        Exclusion criteria:

          -  Subjects in whom a difficult intubation because of anatomical malformations was
             expected;

          -  Subjects known or suspected to have neuromuscular disorders impairing NMB and/or
             significant renal dysfunction (for example a creatinine level &gt; 1.6 mg/dl) and/or
             severe hepatic dysfunction.

          -  Subjects known or suspected to have a (family) history of malignant hyperthermia;

          -  Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other
             medication used during general anesthesia;

          -  Subjects receiving medication expected to interfere with the rocuronium or vecuronium
             given in this trial, based on the dose and time of administration;

          -  Female subjects who were pregnant;

          -  Female subjects of childbearing potential not using birth control or using only oral
             contraception as birth control;

          -  Subjects who were breast-feeding;

          -  Subjects who had already participated in CT 19.4.209B, or in another trial with Org
             25969;

          -  Subjects who had participated in another clinical trial, not preapproved by Organon,
             within 6 months of entering into CT 19.4.209B.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Vecuronium Bromide</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

